New study further validates Bioiberica’s b-2Cool® native type II collagen as trusted source for holistic mobility solutions

New scientific research, published in Osteoarthritis and Cartilage[1], highlights the benefits of Bioiberica’s native (undenatured) type II collagen (b-2Cool®) in combination with other key ingredients for joint health: chondroitin sulphate, glucosamine hydrochloride and hyaluronic acid (Bioiberica’s Mobilee®). For dietary supplement manufacturers seeking easy-to-formulate solutions, the research highlights b-2Cool® as an efficacious ingredient for use in holistic mobility products.

This study is a key development in Bioiberica’s joint health research. It complements previous research by providing additional validation for the benefits of using native type II collagen in innovative mobility solutions and allows Bioiberica to further position b-2Cool® as a trusted ingredient for effective joint health formulations,” says Jaume Reguant, Director of Healthcare at Bioiberica.

As younger, health-conscious consumers take more of an interest in their mobility, the joint health market must evolve to appeal beyond the senior population,” he adds. “These audiences are interested in comprehensive solutions that target overall mobility and help them live life to the fullest as they age. These new results show the effectiveness of combining Bioiberica’s ingredients for joint health and opens up new opportunities for manufacturers looking to expand their portfolio and explore more holistic mobility offerings for consumers.”

The study, conducted in a rabbit model of osteoarthritis, set out to evaluate the effects of b-2Cool® native type II collagen in combination with CS b-Bioactive® chondroitin sulphate, glucosamine hydrochloride and Mobilee® which is a rooster comb extract rich in hyaluronic acid.

During the study, the animals were divided into three groups: a control group, one treated with chondroitin sulphate, glucosamine hydrochloride and Mobilee®, and the third receiving the same combination with the addition of b-2Cool®.

The group which received the formulation comprising b-2Cool® showed a lower degree of cartilage degeneration, signs of less advanced osteoarthritis, healthier cartilage and joints and significantly better synovial membrane values on histology. Adding to Bioiberica’s bank of evidence demonstrating the role of b-2Cool® in joint health, this latest peer-reviewed research indicates the benefits of combining native (undenatured) type II collagen with other key ingredients for enhanced mobility.

Extracted from chicken sternum and manufactured by Bioiberica through a strictly controlled process, a low dose of just 40mg per day of b-2Cool® helps to maintain healthy joints. Native type II collagen exerts its effect through a mechanism of action called oral tolerance, as described by Park et al.[2]

This latest research adds to a range of scientific studies demonstrating the efficacy of b-2Cool®. A safe, naturally-sourced, new generation collagen, b-2Cool® is supported by four preclinical studies and clinical trials which show its effectiveness in providing support for cartilage by preserving endogenous collagen and helping to maintain healthy joints and quality of life, as both a standalone ingredient, and in combined solutions.

To delve deeper into the results of this latest research, you can join Bioiberica at Vitafoods Virtual Expo (7-11 September), during which attendees will be able to attend an exclusive webinar where its experts discuss the efficacy of b-2Cool® in combined ingredient solutions, as well as a standalone ingredient, via the Healthy Ageing Micro-Community.



[1] Sifre, V., Soler, C., Redondo, J. I., Domenech, L., Segarra, S., & Serra, C. I. Macroscopic and histologic improvements in joint cartilage, subchondral bone and synovial membrane with glycosaminoglycans and native type ii collagen in a rabbit model of osteoarthritis. Osteoarthritis and Cartilage 2020, 28, S206.

[2] Park et al. Type II collagen oral tolerance; mechanism and role in collagen-induced arthritis and rheumatoid arthritis. Modern Rheumatology 2009, 19 (6): 581-589.